Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...
PARPi therapy has been a breakthrough for treating ovarian and breast cancers. In high-income countries, most patients with a ...
Zacks Small Cap Research on MSN13d
IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...
These cancers are, however, quite sensitive to anticancer drugs such as poly (ADP-ribose) polymerase inhibitors (PARPi). When successful, these cancer treatments cause enough DNA damage to trigger ...
Without accurate CH classification, these patients could be inappropriately directed toward PARPi therapy. "Without accurate CH classification, oncologists risk recommending therapies based on ...
OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback